26 Jun JAK Inhibitors Offer Hope For Vitiligo
MedicalResearch.com Interview with:
Brett King, M.D., Ph.D.
Assistant Professor of Dermatology
Yale University School of Medicine
Medical Research: What is the background for this study? What are the main findings?
Dr. King: Treatment options for vitiligo are limited and often ineffective. This report highlights the possibility of targeted therapy of vitiligo using a relatively new class of medicines called Janus kinase (JAK) inhibitors. Based upon our understanding of vitiligo, JAK inhibition interrupts interferon gamma signaling, which perpetuates depigmentation.
Medical Research: What should clinicians and patients take away from your report?
Dr. King: There is hope that effective treatments will soon be available for vitiligo.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. King: Clinical trials using different JAK inhibitors, both topically and orally, are needed. Also, we need to better understand how important JAK 1/2 vs JAK 1/3 inhibition is to repigmentation.
Citation:
[wysija_form id=”3″]
Brett King, M.D., Ph.D., Assistant Professor of Dermatology, & Yale University School of Medicine (2015). JAK Inhibitors Offer Hope For Vitiligo
Last Updated on June 26, 2015 by Marie Benz MD FAAD
